344 related articles for article (PubMed ID: 24063976)
1. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants.
Verdijk P; Rots NY; van Oijen MG; Weldon WC; Oberste MS; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2014 Sep; 32(39):4938-44. PubMed ID: 25043278
[TBL] [Abstract][Full Text] [Related]
3. Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba.
Resik S; Tejeda A; Fonseca M; Alemañi N; Diaz M; Martinez Y; Garcia G; Okayasu H; Burton A; Bakker WA; Verdijk P; Sutter RW
Vaccine; 2014 Sep; 32(42):5399-404. PubMed ID: 25131734
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial.
Liao G; Li R; Li C; Sun M; Li Y; Chu J; Jiang S; Li Q
J Infect Dis; 2012 Jan; 205(2):237-43. PubMed ID: 22158682
[TBL] [Abstract][Full Text] [Related]
5. First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age.
Lindgren LM; Tingskov PN; Justesen AH; Nedergaard BS; Olsen KJ; Andreasen LV; Kromann I; Sørensen C; Dietrich J; Thierry-Carstensen B
Vaccine; 2017 Jan; 35(4):596-604. PubMed ID: 28027810
[TBL] [Abstract][Full Text] [Related]
6. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine.
Hotta C; Ogawa T; Shirasawa H
Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843
[TBL] [Abstract][Full Text] [Related]
7. [Immunogenicity and safety of a booster dose of inactivated polio vaccine].
Li XM; Zhang ZJ; Wang HH; Liu F; Zhang LW; Chu P; Xu Y; Zhang HR; Li J; Liu DL; Lu L
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Oct; 47(10):905-9. PubMed ID: 24378129
[TBL] [Abstract][Full Text] [Related]
8. Phase 3 Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine.
Liao G; Li R; Li C; Sun M; Jiang S; Li Y; Mo Z; Xia J; Xie Z; Che Y; Yang J; Yin Z; Wang J; Chu J; Cai W; Zhou J; Wang J; Li Q
J Infect Dis; 2016 Dec; 214(11):1728-1734. PubMed ID: 27658691
[TBL] [Abstract][Full Text] [Related]
9. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
[TBL] [Abstract][Full Text] [Related]
11. Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats.
Andreasen LV; Hansen LB; Andersen P; Agger EM; Dietrich J
Vaccine; 2015 Apr; 33(15):1873-9. PubMed ID: 25698487
[TBL] [Abstract][Full Text] [Related]
12. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
Bakker WA; Thomassen YE; van't Oever AG; Westdijk J; van Oijen MG; Sundermann LC; van't Veld P; Sleeman E; van Nimwegen FW; Hamidi A; Kersten GF; van den Heuvel N; Hendriks JT; van der Pol LA
Vaccine; 2011 Sep; 29(41):7188-96. PubMed ID: 21651934
[TBL] [Abstract][Full Text] [Related]
13. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.
Sanders BP; Oakes Ide L; van Hoek V; Liu Y; Marissen W; Minor PD; Wimmer E; Schuitemaker H; Custers JH; Macadam A; Cello J; Edo-Matas D
Vaccine; 2015 Nov; 33(48):6611-6. PubMed ID: 26529068
[TBL] [Abstract][Full Text] [Related]
14. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults.
Soonawala D; Verdijk P; Wijmenga-Monsuur AJ; Boog CJ; Koedam P; Visser LG; Rots NY
Vaccine; 2013 Aug; 31(36):3688-94. PubMed ID: 23770332
[TBL] [Abstract][Full Text] [Related]
15. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement.
Chen H; Gao Z; Bai S; Liu X; Han S; Xiao Y; Liu F; Yu Y; Sun H; Yang X
Vaccine; 2021 Apr; 39(17):2467-2474. PubMed ID: 33810904
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial.
Cramer JP; Jimeno J; Han HH; Lin S; Hartmann K; Borkowski A; Sáez-Llorens X
Vaccine; 2020 Jul; 38(33):5313-5323. PubMed ID: 32563609
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults.
Leroux-Roels I; Leroux-Roels G; Shukarev G; Schuitemaker H; Cahill C; de Rooij R; Struijs M; van Zeeburg H; Jacquet JM
Hum Vaccin Immunother; 2021 May; 17(5):1366-1373. PubMed ID: 33175637
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial.
Chu K; Ying Z; Wang L; Hu Y; Xia J; Chen L; Wang J; Li C; Zhang Q; Gao Q; Hu Y
Vaccine; 2018 Oct; 36(45):6782-6789. PubMed ID: 30249424
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age.
Bravo LC; Carlos JC; Gatchalian SR; Montellano MEB; Tabora CFCB; Thierry-Carstensen B; Tingskov PN; Sørensen C; Wachmann H; Bandyopadhyay AS; Nielsen PI; Kusk MV
Vaccine; 2020 Jan; 38(3):530-538. PubMed ID: 31703934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
